Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy

被引:25
作者
Brown, AJL
Korber, BT
Condra, JH
机构
[1] Univ Edinburgh, Inst Cell Anim & Populat Biol, Ctr HIV Res, Edinburgh EH9 3JN, Midlothian, Scotland
[2] Univ Calif Los Alamos Natl Lab, GRP T10, Los Alamos, NM 87545 USA
[3] Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA
关键词
D O I
10.1089/088922299311420
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Significant diversity exists in amino acid sequences encoding HIV-1 protease in individuals naive for protease inhibitors, which could influence the rate of evolution of resistance. High-level resistance to indinavir requires multiple substitutions among at least 11 amino acid sites, and no single substitution was observed in all of 29 resistant isolates obtained from patients on long-term indinavir monotherapy, We have analyzed the evolution of PR in these sequences. The divergence from the baseline amino acid sequence by week 24 was 4%, increasing more than 7% by week 60, The mean difference between sequences from different patients at baseline was 6% (3-9%), rising to 10% after 40 weeks (3-16%), although at all time points nonsynonymous substitutions were less frequent than synonymous nucleotide changes, Analysis of associations between variants at different amino acid sites using a mutual information statistic revealed four pairs of sites to be significantly associated. In three cases these associations included residue 82, Clusters of baseline and week 24 amino acid sequences identified by maximum parsimony did not correlate significantly with the IC95 to indinavir, although a weak correlation of baseline clusters with phenotype at the week 24 time point was suggested.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 29 条
  • [1] TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-INFECTED CELLS WITH COMBINATIONS OF HIV-1-SPECIFIC INHIBITORS RESULTS IN A DIFFERENT RESISTANCE PATTERN THAN DOES TREATMENT WITH SINGLE-DRUG THERAPY
    BALZARINI, J
    KARLSSON, A
    PEREZPEREZ, MJ
    CAMARASA, MJ
    TARPLEY, WG
    DECLERCQ, E
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (09) : 5353 - 5359
  • [2] Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population
    Brown, AJL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) : 1862 - 1865
  • [3] HIV-1: Gambling on the evolution of drug resistance?
    Brown, AJL
    Richman, DD
    [J]. NATURE MEDICINE, 1997, 3 (03) : 268 - 271
  • [4] Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
    Condra, JH
    Holder, DJ
    Schleif, WA
    Blahy, OM
    Danovich, RM
    Gabryelski, LJ
    Graham, DJ
    Laird, D
    Quintero, JC
    Rhodes, A
    Robbins, HL
    Roth, E
    Shivaprakash, M
    Yang, T
    Chodakewitz, JA
    Deutsch, PJ
    Leavitt, RY
    Massari, FE
    Mellors, JW
    Squires, KE
    Steigbigel, RT
    Teppler, H
    Emini, EA
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (12) : 8270 - 8276
  • [5] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS
    CONDRA, JH
    SCHLEIF, WA
    BLAHY, OM
    GABRYELSKI, LJ
    GRAHAM, DJ
    QUINTERO, JC
    RHODES, A
    ROBBINS, HL
    ROTH, E
    SHIVAPRAKASH, M
    TITUS, D
    YANG, T
    TEPPLER, H
    SQUIRES, KE
    DEUTSCH, PJ
    EMINI, EA
    [J]. NATURE, 1995, 374 (6522) : 569 - 571
  • [6] TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER
    ERON, JJ
    BENOIT, SL
    JEMSEK, J
    MACARTHUR, RD
    SANTANA, J
    QUINN, JB
    KURITZKES, DR
    FALLON, MA
    RUBIN, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) : 1662 - 1669
  • [7] Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
  • [8] FROST SDW, UNPUB GENETIC STRCTU
  • [9] INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C(2) SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
    HOSUR, MV
    BHAT, TN
    KEMPF, DJ
    BALDWIN, ET
    LIU, BS
    GULNIK, S
    WIDEBURG, NE
    NORBECK, DW
    APPELT, K
    ERICKSON, JW
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (03) : 847 - 855
  • [10] PHASE-I/PHASE-II STUDY OF 3TC (LAMIVUDINE) IN HIV-POSITIVE, ASYMPTOMATIC OR MILD AIDS-RELATED COMPLEX PATIENTS - SUSTAINED REDUCTION IN VIRAL MARKERS
    INGRAND, D
    WEBER, J
    BOUCHER, CAB
    LOVEDAY, C
    ROBERT, C
    HILL, A
    CAMMACK, N
    KATLAMA, C
    TUBIANA, R
    VALENTIN, MA
    GENTILINI, M
    VANLEEUWEN, R
    DANNER, SA
    KITCHEN, V
    MCBRIDE, M
    [J]. AIDS, 1995, 9 (12) : 1323 - 1329